Top

Reactions Weekly

Published in:

01-04-2024 | Multiple Myeloma | Case report

Belantamab-mafodotin

Keratopathy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

De La Rubia J, et al. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort. Blood 140 (Suppl. 1) : 4315-4317, Nov 2022. Available from: URL: https://dx.doi.org/10.1182/blood-2022-158538 [abstract]

Title: Belantamab-mafodotin
Keratopathy
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keyword: Multiple Myeloma
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-55992-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Belantamab-mafodotin

Keratopathy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Octreotide

Dulaglutide

Alpha-ketoglutaric-acid/arginine/calcium-beta-hydroxybutyrate/KTX-0101/magnesium-beta-hydroxybutyrate/medium-chain-triglyceride-oil/7-oxo-prasterone

Testosterone

Multiple drugs

Iodine